(Press-News.org) Under strict embargo until Tuesday 11 June 2024 at 23.30 hours UK (BST) time
Preparing for a world where Alzheimer’s disease is treatable
Peer-reviewed | Observational study | People
Drugs with the potential to change the course of Alzheimer’s disease are expected to be approved by mid-year in the UK. Healthcare services may need to change to ensure that all patients have equitable access to these new modifying anti-amyloid therapies, according to research led by Queen Mary University of London and University College London (UCL).
Alzheimer’s disease is the most common cause of dementia. Of the 944,000 people living with dementia in the UK, 60-80% have Alzheimer’s. Currently, the only available drugs for Alzheimer’s treat symptoms. However, recent clinical trials show that new therapies – which use monoclonal antibodies to remove amyloid plaques that form on the brain – may slow down disease progression. Two of these 'disease-modifying therapies' (DMTs) have been granted 'breakthrough therapy' designation in the UK and are likely to become available to patients by mid-2024 (pending regulatory approval).
In the UK, dementia care is mostly centred around psychiatry-led memory clinics in the community. In their current state, it is extremely unlikely that DMTs will be administered in these settings. Delivery of these new treatments will require a major restructure to existing dementia services – from determining eligibility to delivery of the treatment itself, including follow-up. It will require additional staff and training across imaging, diagnostics and pathology, and other clinical services. It will also require access to laboratories that can carry out biomarker testing to confirm whether a patient is eligible for the treatment.
The potential roll-out of DMTs presents major challenges for services and has real potential to amplify existing inequities in service access. To anticipate and mitigate these challenges, researchers from Queen Mary’s Centre for Preventive Neurology, UCL’s Dementia Research Centre, and UCL Partners carried out essential research to estimate how many patients are likely to be eligible for DMTs.
The researchers compared clinical case notes from over 1,000 people attending either community memory clinics or specialist cognitive services in England. They found that 32% of those attending memory services and 14% of people attending specialist cognitive services would likely be referred for consideration for the new DMTs. Researchers found that amyloid biomarker tests were available for people attending specialist cognitive services in the form of specialist scans called PET scans and spinal fluid tests. However, fewer than 1% of people attending community memory clinics had undergone biomarker tests.
While a sizeable proportion of patients attending memory clinics may be referred for therapy for Alzheimer’s disease, only a minority are likely to be suitable, once they have undergone biomarker testing. The researchers highlight an immediate need for biomarker testing to ensure that the right patients can be identified for these treatments.
First author, Professor Ruth Dobson, Professor of Neurology at Queen Mary University of London, Consultant Neurologist and Dementia Theme Co-Lead for UCL Partners, said: “The development of disease modifying therapies for dementia has the potential to drive significant service changes. We have seen the impact of this in MS and stroke. It is crucial to understand and plan such changes proactively in order to ensure best care for all people living with dementia, regardless of initial treatment availability and eligibility.”
Study lead, Professor Rimona Weil, Consultant Neurologist at UCL and the National Hospital for Neurology and Neurosurgery, and Dementia Theme Co-Lead for UCL Partners said: “Working with clinicians running memory clinics was crucial to this work, meaning that we could get real-world estimates for how many people are likely to be referred for these new drugs for the first time.”
Study co-lead, Professor Catherine Mummery, Consultant Neurologist at UCL and the National Hospital for Neurology and Neurosurgery, said: “We demonstrate that diagnostic resources affect the accuracy of diagnosis and referral habits, and that a collaborative networked approach is critical to developing a functioning treatment service in preparation for these new therapies”.
David Thomas, Head of Policy and Public Affairs at Alzheimer’s Research UK, said: “New Alzheimer’s drugs are finally on the horizon, but for their full potential to be realised, health systems need to be able to offer people with symptoms of dementia an accurate and early diagnosis to find out whether these treatments could benefit them.
“As this research demonstrates, the NHS is a long way from being able to do this testing routinely. Whoever forms the next government must invest in the NHS urgently, to ensure we have the right diagnostics and workforce in place to help identify people who could benefit from new treatments should they be deemed safe and effective by the regulators. A key part of the solution is cheaper, more scalable diagnostics, such as blood tests, for use in clinical care.”
This study was produced by researchers from a network of universities who form the Academic Health Science Centre for UCLPartners and in collaboration with a network of clinicians in memory clinics in London and the South East.
NOTES TO EDITORS
Contact:
Sophia Prout
Faculty Communications Manager – Medicine and Dentistry
Queen Mary University of London
Email: s.prout@qmul.ac.uk or press@qmul.ac.uk
Phone: 07718136512
Paper details:
Ruth Dobson et al. “Eligibility for anti-amyloid treatment: preparing for disease modifying therapies for Alzheimer’s disease.” Published in Journal of Neurology, Neurosurgery and Psychiatry.
DOI: 10.1136/jnnp-2024-333468
Available after publication at: (to follow)
Under strict embargo until Tuesday 11 June 2024 at 23.30 hours UK (BST) time.
A copy of the paper is available upon request.
Funding information:
Rimona Weil is funded by a Wellcome Clinical Research Career Development Fellowship (205167/Z/16/Z).
Cath Mummery was partly funded by the NIHR UCLH BRC.
Conflicts of Interest Disclosures:
Ruth Dobson has received honoraria for speaking and/or traveling from Biogen, Merck, Teva, Janssen and Sanofi. She served on advisory board of Roche, Biogen, Janssen and Merck. She has received grant support from Biogen, Merck, Celgene, Barts Charity, the UK MS Society, NMSS, MRC and the Home Family Charitable Trust.
Rimona S. Weil has received honoraria from GE Healthcare, Bial and Britannia, and consultancy fees from Therakind.
Cath J. Mummery has undertaken Advisory board/ consultancy for Biogen, Roche, WAVE, IONIS, Prevail, Lilly, grant income from Biogen and Speaker honoraria for Biogen, Roche, EISAI, IONIS, Lilly.
About Queen Mary
www.qmul.ac.uk
At Queen Mary University of London, we believe that a diversity of ideas helps us achieve the previously unthinkable.
Throughout our history, we’ve fostered social justice and improved lives through academic excellence. And we continue to live and breathe this spirit today, not because it’s simply ‘the right thing to do’ but for what it helps us achieve and the intellectual brilliance it delivers.
Our reformer heritage informs our conviction that great ideas can and should come from anywhere. It’s an approach that has brought results across the globe, from the communities of east London to the favelas of Rio de Janeiro.
We continue to embrace diversity of thought and opinion in everything we do, in the belief that when views collide, disciplines interact, and perspectives intersect, truly original thought takes form.
About UCL Partners
UCLPartners are a health innovation partnership. Our mission is to help five million people from North London to the Essex coast live longer, healthier lives. We focus on the health challenges that have the biggest impact on the people most in need. Our work aims to prevent people from becoming ill, give them quicker access to care and transform the quality of their treatment.
END
Preparing for a world where Alzheimer’s disease is treatable
2024-06-12
ELSE PRESS RELEASES FROM THIS DATE:
Robot radiotherapy could improve treatments for eye disease
2024-06-12
Researchers from King’s, with doctors at King’s College Hospital NHS Foundation Trust, have successfully used a new robot system to improve treatment for debilitating eye disease.
The custom-built robot was used to treat wet neovascular age-related macular degeneration (AMD), administering a one-off, minimally invasive dose of radiation, followed by patients’ routine treatment with injections into their eye.
In the landmark trial, published today in The Lancet, it was found that patients then needed fewer injections to effectively control the disease, potentially saving around ...
Millions of insects migrate through 30-metre Pyrenees pass
2024-06-12
Over 17 million insects migrate each year through a single mountain pass on the border between France and Spain, new research shows.
University of Exeter scientists studied migrating insects in the Pass of Bujaruelo, a 30-metre gap between two high peaks in the Pyrenees.
The team visited the pass each autumn for four years, monitoring the vast number and variety of day-flying insects heading south.
The findings for this single pass suggest that billions of insects cross the Pyrenees each year, making it a key location for many migrating species.
The migrating insects ...
Should celebrities and influencers turn off their social media comments? A new study suggests they are less persuasive and likable when they do
2024-06-12
Researchers from University of Alabama and Vanderbilt University published a new Journal of Marketing study that examines the negative consequences that celebrities and influences incur when they disable social media comments.
The study, forthcoming in the Journal of Marketing, is titled “No Comments (From You): Understanding the Interpersonal and Professional Consequences of Disabling Social Media Comments” and is authored by Michelle Daniels and Freeman Wu.
Celebrities and influencers like Addison Rae, Hailey Bieber, ...
Painful truth about knee osteoarthritis: Why inactivity may be more complex than we think
2024-06-12
Knee osteoarthritis (OA) is a common cause of pain and joint stiffness. And while physical activity is known to ease symptoms, only one in 10 people regularly exercise.
Understanding what contributes to patients’ inactivity is the focus of a world first study from the University of South Australia. Here, researchers have found that people with knee OA unconsciously believe that activity may be dangerous to their condition, despite medical advice telling them otherwise.
The study found that of those surveyed, 69% of people with knee pain had stronger implicit (unconscious) beliefs that exercise ...
New study finds human-caused nitrous oxide emissions grew 40 percent from 1980-2020, greatly accelerating climate change
2024-06-12
Chestnut Hill, Mass. (6/11/24) – Emissions of nitrous oxide – a greenhouse gas more potent than carbon dioxide or methane – continued unabated between 1980 and 2020, a year when more than 10-million metric tons were released into the atmosphere primarily through farming practices, according to a new report by the Global Carbon Project.
Agricultural production accounted for 74 percent of human-driven nitrous oxide emissions in the 2010s – attributed primarily to the use of chemical fertilizers and ...
Study reveals significant increasing nitrous-oxide emissions from human activities, jeopardizing climate goals
2024-06-12
Emissions of nitrous-oxide (N2O) - a potent greenhouse gas - have continued to rise unabated over the past four decades, according to an international team of scientists.
The new report 'Global nitrous oxide budget (1980–2020)' is published in the journal Earth System Science Data. It is the most comprehensive accounting to date of nitrous-oxide emissions from human activities and natural sources.
It was led by researchers from Boston College in the US and involved an international team of scientists including researchers from the University of East Anglia (UEA), UK, under the umbrella of the Global Carbon Project. ...
Virtual reality as a reliable shooting performance-tracking tool
2024-06-11
COLUMBUS, Ohio – Virtual reality technology can do more than teach weaponry skills in law enforcement and military personnel, a new study suggests: It can accurately record shooting performance and reliably track individuals’ progress over time.
In the study of 30 people with a range of experience levels in handling a rifle, researchers at The Ohio State University found that a ballistic simulator captured data on the shooters’ accuracy, decision-making and reaction time – down to the millimeter in distance ...
New study explores the sun’s effects on the skin microbiome – it can create a damaged skin barrier
2024-06-11
The impact of solar radiation on skin has long been understood but what about UV’s effects on our skin's hidden world – its microbiome?
An article from American Society for Photobiology’s journal delved into existing knowledge on solar radiation’s impact on the skin microbiome and proposed innovative sun protection methods that safeguard both skin integrity and microbiome balance.
Experts offered insights into novel sun protection products designed to shield the skin and mitigate the effects of solar ...
States declare May 17 as NEC Awareness Day
2024-06-11
The NEC Society is leading the way toward a world without necrotizing enterocolitis (NEC), a complex and often deadly intestinal disease affecting the most vulnerable infants. By bringing together families and elected officials, the NEC Society is raising the profile of this devastating neonatal disease. States nationwide have championed NEC Awareness Day Resolutions to recognize May 17.
The NEC Society’s families have partnered with elected officials to declare May 17 NEC Awareness Day in California, Colorado, Georgia, Louisiana, New York, Pennsylvania, and Utah, bringing much-needed attention to this leading cause ...
Precision medicine for sepsis in children within reach
2024-06-11
Sepsis – the leading cause of mortality in children around the world – can present with a wide range of signs and symptoms, making a one-size-fits-all treatment strategy ineffective. Pursuing a precision medicine approach for pediatric sepsis, researchers used artificial intelligence to analyze a large set of clinical data and find a distinct group of patients who might respond better to targeted treatments.
These children share clinical characteristics described as PHES, or persistent hypoxemia (abnormally low oxygen ...